A UNIQUE CELL-SURFACE ANTIGEN IDENTIFYING LYMPHOID MALIGNANCIES OF B-CELL ORIGIN
A UNIQUE CELL-SURFACE ANTIGEN IDENTIFYING LYMPHOID MALIGNANCIES OF B-CELL ORIGIN
复制标题
DOI：
10.1172/jci110005
复制
发表时间：
1981-01-01
影响因子：
15.9
通讯作者：
STASHENKO, P
中科院分区：
文献类型：
--
作者：
NADLER, LM;RITZ, J;STASHENKO, P
一种对独特的B细胞表面分化抗原具有特异性的单克隆抗体（抗B1）被用于表征白血病或淋巴瘤患者的恶性细胞。来自淋巴瘤或慢性淋巴细胞白血病患者的所有肿瘤细胞，带有单克隆. kappa。或... L链，表达B1抗原。来自T细胞白血病和淋巴瘤或急性成髓细胞白血病的肿瘤细胞不反应。大约50%的非T细胞来源的急性淋巴细胞白血病（ALL）和50%的慢性髓细胞白血病急变期也有抗B1反应。在28例常见ALL抗原（CALLA）阳性的ALL患者中，21例抗B1阳性; 13例CALLA阴性的ALL患者中0例反应性。存在于正常B细胞上的抗原在绝大多数B细胞淋巴瘤上表达，并且在75%的CALLA阳性ALL，表明这些肿瘤可能具有共同的B细胞谱系。
A monoclonal antibody (anti-B1) specific for a unique B cell surface differentiation antigen was used to characterize the malignant cells from patients with leukemias or lymphomas. All tumor cells from patients with lymphomas or chronic lymphocytic leukemias, bearing monoclonal .kappa. or .lambda. L chain, expressed the B1 antigen. Tumor cells from T cell leukemias and lymphomas or acute myeloblastic leukemias were unreactive. Approximately 50% of acute lymphoblastic leukemias (ALL) of non-T origin and 50% of chornic myelocytic leukemia in blast crisis were also anti-B1 reactive. Of 28 patients with the common ALL antigen (CALLA) positive form of ALL, 21 were anti-B1 positive; 0 of 13 patients with CALLA negative ALL were reactive. An antigen present on normal B cells is expressed on the vast majority of B cell lymphomas and on .apprx. 75% of CALLA positive ALL, suggesting that these tumors may share a common B cell lineage.